Savara Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare respiratory diseases
The company is dedicated to improving the lives of patients with unmet medical needs by harnessing its expertise in inhalation therapy and drug delivery. Savara's ambitious pipeline includes candidates aimed at addressing conditions such as pulmonary diseases, and its research is driven by a commitment to scientific excellence and patient outcomes. Through collaboration and cutting-edge technology, Savara strives to bring new and effective therapies to market, ultimately enhancing the quality of life for those affected by respiratory ailments.
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms.
U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQTARS) shares rose 12.3% to $22.59.
The Dow Jones closed higher by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
The Dow Jones edged lower on the first trading session of 2023. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Savara (NASDAQSVRA) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Savara reported in-line EPS of $-0.06 versus an estimate of $-0.06.
Savara (NASDAQSVRA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Savara beat estimated earnings by 28.57%, reporting an EPS of $-0.05 versus an estimate of $-0.07.
